VIBATIV offers comparable efficacy to vancomycin in a difficult-to-treat patient population.
Of the 797 patients in the Modified All-Treated (MAT) population with at least 1 Gram–positive respiratory pathogen at baseline:1
* VIBATIV is not indicated for the treatment of bacteremia.